A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2012
At a glance
- Drugs TV 5010 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Teva Italy
- 25 Oct 2012 Last checked against the European Clinical Trials Database record.
- 17 May 2011 New trial record